Document is current
Any future updates will be listed below
-
Authors
Saxena, Neetu
Beraldi, Eliana
Fazli, Ladan
Somasekharan, Syam Prakash https://orcid.org/0000-0002-9006-8206
Adomat, Hans
Zhang, Fan
Molokwu, Chidi
Gleave, Anna
Nappi, Lucia
Nguyen, Kimberly https://orcid.org/0000-0001-7983-1816
Brar, Pavn
Nikesitch, Nicholas
Wang, Yuzhuo https://orcid.org/0000-0002-9749-8591
Collins, Colin
Sorensen, Poul H https://orcid.org/0000-0001-7447-2199
Gleave, Martin https://orcid.org/0000-0003-4235-0167
-
Funding
Funding for this research was provided by:
Terry Fox New Frontiers Program Project (1062)
- License Information
-
More Information
Article History
Received: 9 September 2020
Revised: 5 February 2021
Accepted: 9 February 2021
First Online: 11 March 2021
Conflict of interest
: The University of British Columbia has granted patents on the Hsp27 antisense OGX‐427. A patent application (62/756,707) has been submitted applications on ivermectin analogues for the treatment of cancer, listing Dr. Martin E. Gleave as inventor.
